Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Cassava Sciences Completes Enrollment For Pivotal Phase 3 Program Of Simufilam In Alzheimer's Disease

Author: Benzinga Newsdesk | November 06, 2023 10:16am

1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia.
Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end 2024.
- Top-line results for on-going, 76-week Phase 3 trial expected approximately mid-year 2025.

Posted In: SAVA